1007877-99-7

Basic information

• Product Name: (R)-2-(4-hydroxypiperidin-1-yl)-2-phenylacetic acid
• CAS NO: 1007877-99-7
• Molecular Weight: 235.283
• Mol File: 1007877-99-7.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: (R)-2-(4-hydroxypiperidin-1-yl)-2-phenylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(4-hydroxypiperidin-1-yl)-2-phenylacetic acid(1007877-99-7)
• EPA Substance Registry System: (R)-2-(4-hydroxypiperidin-1-yl)-2-phenylacetic acid(1007877-99-7)

Safety Data

• Hazardous Substances Data: 1007877-99-7(Hazardous Substances Data)

Upstream product

• 1007877-95-3 benzyl (S)-2-(4-hydroxypiperidin-1-yl)-2-phenylacetate 
• 62173-99-3 benzyl 2-hydroxy-2-phenylacetate 

Relevant articles and documents

HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives

The isoquinolinamide series of HCV NS5A inhibitors exemplified by compounds 2b and 2c provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a replicons compared to that of the initial program lead, stilbene 2a. Structure-activity relationship (SAR) studies that uncovered an alternate phenylglycine-based cap series that exhibit further improvements in virology profile, along with some insights into the pharmacophoric elements associated with the GT-1a potency, are described.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.